Latest Breaking News On - Medalliance chairman - Page 8 : comparemela.com

MedAlliance announces completion of enrollment in Japanese SELUTION SLR Study

MedAlliance announces completion of enrollment in Japanese SELUTION SLR Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSwitzerland generalRichard kenyonKostenloser wertpapierhandelPrnewswire medallianceMa med allianceDevice agencyCell adherent technologySirolimus drug eluting balloonClinical trial notificationMedical device agencyMajor adversePrimary patencyMedalliance chairmanஒன்றுபட்டது மாநிலங்களில்

MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study

MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSwitzerland generalRichard kenyonMa med allianceCell adherent technologyMedalliance chairmanஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்ரிச்சர்ட் கெந்யந்மா மேட் கூட்டணி

12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR™ Presented as Late Breaking Trial at LINC

Share this article Share this article NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). 12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR™ Presented as Late Breaking Trial at LINC The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data.

United statesGlasgow cityUnited kingdomTec chongRichard kenyonTjun yip tangDrug administrationCell adherent technologyHospital department of vascular surgerySingapore general hospitalAssociate professorTze tec chongSenior consultantsPeripheral artery diseaseMedalliance chairmanBreakthrough device designation status

12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR Presented as Late Breaking Trial at LINC

12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR Presented as Late Breaking Trial at LINC NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data.

United statesGlasgow cityUnited kingdomTec chongRichard kenyonKostenloser wertpapierhandelTjun yip tangDrug administrationCell adherent technologyHospital department of vascular surgeryLate breaking trialCritical limb ischemiaMonth below the knee dataPrimary patency rateTarget lesion revascularizationAmputation free survival

12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR™ [ ] | Comunicati stampa CataniaOggi

28 gennaio 2021 17:40 Fonte: Adnkronos #salute-e-benessere NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data.

United statesGlasgow cityUnited kingdomTec chongTjun yip tangDrug administrationCell adherent technologyHospital department of vascular surgeryLate breaking trialCritical limb ischemiaPrimary patency rateTarget lesion revascularizationAmputation free survivalSingapore general hospitalAssociate professorTze tec chong